Mersana Therapeutics, Inc.

NasdaqGS:MRSN Lagerbericht

Marktkapitalisierung: US$223.3m

Mersana Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Mersana Therapeutics is forecast to grow earnings and revenue by 12.4% and 35.1% per annum respectively. EPS is expected to grow by 13.2% per annum. Return on equity is forecast to be -156.7% in 3 years.

Wichtige Informationen

12.4%

Wachstumsrate der Gewinne

13.2%

EPS-Wachstumsrate

Biotechs Gewinnwachstum27.1%
Wachstumsrate der Einnahmen35.1%
Zukünftige Eigenkapitalrendite-156.7%
Analystenabdeckung

Good

Zuletzt aktualisiert30 Sep 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Shares Fly 29% But Investors Aren't Buying For Growth

Oct 03
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Shares Fly 29% But Investors Aren't Buying For Growth

Things Look Grim For Mersana Therapeutics, Inc. (NASDAQ:MRSN) After Today's Downgrade

Aug 15
Things Look Grim For Mersana Therapeutics, Inc. (NASDAQ:MRSN) After Today's Downgrade

Investors Don't See Light At End Of Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) Tunnel And Push Stock Down 32%

Aug 13
Investors Don't See Light At End Of Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) Tunnel And Push Stock Down 32%

Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) 25% Dip In Price Shows Sentiment Is Matching Revenues

Jun 19
Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) 25% Dip In Price Shows Sentiment Is Matching Revenues

Mersana Therapeutics: On Hold While Waiting For Any Positive News

May 15

Investors Don't See Light At End Of Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) Tunnel And Push Stock Down 33%

Apr 25
Investors Don't See Light At End Of Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) Tunnel And Push Stock Down 33%

Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) Shares Bounce 26% But Its Business Still Trails The Industry

Feb 27
Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) Shares Bounce 26% But Its Business Still Trails The Industry

Mersana Therapeutics: A Bottom-Feeding Gamble Of A Stock

Jan 11

Here's Why Mersana Therapeutics (NASDAQ:MRSN) Can Manage Its Debt Despite Losing Money

Oct 14
Here's Why Mersana Therapeutics (NASDAQ:MRSN) Can Manage Its Debt Despite Losing Money

Is Mersana Therapeutics (NASDAQ:MRSN) A Risky Investment?

Jun 09
Is Mersana Therapeutics (NASDAQ:MRSN) A Risky Investment?

Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) Intrinsic Value Is Potentially 22% Below Its Share Price

Feb 22
Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) Intrinsic Value Is Potentially 22% Below Its Share Price

Mersana gains as FDA grants fast track status for breast cancer drug

Sep 12

Mersana Therapeutics: Savvy Partnering But Further Progress Is Needed

Aug 15

Taking The Measure Of Mersana Therapeutics

Jan 10

Mersana: ADC Developer With New INDs, Sufficient Cash, And XMT-1536 Progress

Jun 29

It's Unlikely That The CEO Of Mersana Therapeutics, Inc. (NASDAQ:MRSN) Will See A Huge Pay Rise This Year

Jun 05
It's Unlikely That The CEO Of Mersana Therapeutics, Inc. (NASDAQ:MRSN) Will See A Huge Pay Rise This Year

Mersana Therapeutics EPS misses by $0.11, misses on revenue

May 10

Is Mersana Therapeutics (NASDAQ:MRSN) A Risky Investment?

Mar 23
Is Mersana Therapeutics (NASDAQ:MRSN) A Risky Investment?

Did Mersana Therapeutics, Inc. (NASDAQ:MRSN) Insiders Buy Up More Shares?

Jan 29
Did Mersana Therapeutics, Inc. (NASDAQ:MRSN) Insiders Buy Up More Shares?

Bain Capital discloses 4.8% stake in Mersana Therapeutics

Jan 13

Mersana: XMT-1536's Complications, New CMO, And 2H 2021's Critical Catalyst

Jan 11

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:MRSN - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
DatumUmsatzGewinneFreier CashflowBargeld aus operativen TätigkeitenDurchschn. Anz. Analysten
12/31/202646-114-90-879
12/31/202529-98-81-7810
12/31/202425-89-77-7710
6/30/202430-105-134-133N/A
3/31/202438-135-174-173N/A
12/31/202337-172-171-169N/A
9/30/202341-197-191-188N/A
6/30/202339-215-90-87N/A
3/31/202332-213-73-70N/A
12/31/202227-204-52-49N/A
9/30/202212-208-42-41N/A
6/30/20226-194-132-131N/A
3/31/20222-183-122-121N/A
12/31/20210-170-141-140N/A
9/30/20210-150-116-115N/A
6/30/20210-127-100-99N/A
3/31/20211-106-81-80N/A
12/31/20201-88-75-75N/A
9/30/20201-75-70-70N/A
6/30/20202-70-66-66N/A
3/31/20201-67-65-64N/A
12/31/201942-28-68-68N/A
9/30/201943-34-72-71N/A
6/30/201945-35-66-65N/A
3/31/201949-30-64-63N/A
12/31/201811-64-57-55N/A
9/30/201813-56-52-50N/A
6/30/201817-46-53-51N/A
3/31/201816-43N/A-49N/A
12/31/201718-39N/A-43N/A
9/30/201726-23N/A-19N/A
6/30/201723-22N/A-12N/A
3/31/201726-16N/A-11N/A
12/31/201625-14N/A32N/A
12/31/201510-16N/A-10N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: MRSN is forecast to remain unprofitable over the next 3 years.

Ertrag vs. Markt: MRSN is forecast to remain unprofitable over the next 3 years.

Hohe Wachstumserträge: MRSN is forecast to remain unprofitable over the next 3 years.

Einnahmen vs. Markt: MRSN's revenue (35.1% per year) is forecast to grow faster than the US market (8.9% per year).

Hohe Wachstumseinnahmen: MRSN's revenue (35.1% per year) is forecast to grow faster than 20% per year.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: MRSN is forecast to be unprofitable in 3 years.

Wachstumsunternehmen entdecken

7D

1Y

7D

1Y

7D

1Y